drugset / Trial / NCT05388279
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.
Timeline
- Start
- 2022-04-28
- Primary completion
- 2022-09-19
- Completion
- 2022-09-19
Outcome
Outcome not reported
Stopped (Business): “Due to the adjustment and change of the sponsor's R\&D strategy, we now plan to voluntarily terminate this clinical trial.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS012 | Unknown | — | Intravenous |
Indications
No indication recorded.